Avalon GloboCare Announces Notice Of Publication For Key U.S. Patent Filed Jointly With The Massachusetts Institute Of Technology
Portfolio Pulse from Happy Mohamed
Avalon GloboCare Corp. (NASDAQ:ALBT) and the Massachusetts Institute of Technology (MIT) have received a Notice of Publication for U.S. Patent No. 11,555,060, titled 'QTY Fc Fusion Water Soluble Receptor Proteins.' The patent covers the composition of matter and methodology for multiple novel QTY-Code modified cytokine and chemokine protein receptor molecules. The technology can turn water-insoluble transmembrane receptor proteins into water-soluble proteins, potentially expanding the repertoire of selected therapeutic targets against cancers and other diseases.
September 05, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The publication of the patent could potentially boost Avalon GloboCare's reputation as a developer of innovative precision diagnostics and provider of clinical laboratory services. The patented technology could expand the range of therapeutic targets, potentially leading to new revenue streams.
The patent is directly related to Avalon GloboCare's core business of developing innovative precision diagnostics. The patented technology could potentially expand the range of therapeutic targets, which could lead to the development of new products and services, potentially increasing the company's revenues and positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100